Recent progress in prion and prion-like protein aggregation

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 6, 2013, Pages 520-526

  Yi, Chuan Wei ^a   Xu, Wen Chang ^a   Chen, Jie ^a   Liang, Yi ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Macromolecular crowding; Physiological environment; Prion protein; Prion like protein; Protein misfolding

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; PRION PROTEIN; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ANIMAL; HUMAN; MACROMOLECULAR CROWDING; METABOLISM; PHYSIOLOGICAL ENVIRONMENT; PRION; PRION-LIKE PROTEIN; PROTEIN BINDING; PROTEIN MISFOLDING; PROTEIN PROCESSING; PROTEOSTASIS DEFICIENCY; REVIEW;

MACROMOLECULAR CROWDING; PHYSIOLOGICAL ENVIRONMENT; PRION PROTEIN; PRION-LIKE PROTEIN; PROTEIN MISFOLDING;

ANIMALS; HUMANS; PRIONS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOSTASIS DEFICIENCIES; SUPEROXIDE DISMUTASE; TAU PROTEINS;

ANIMALIA; BOS; BOVINAE; OVIS ARIES;

EID: 84879244126     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt052     Document Type: Review

References (69)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998, 95: 13363-13383.
2. Soto C. Prion hypothesis: the end of the controversy? Trends Biochem Sci 2010, 818: 1-8.
3. Alper T, Cramp WA, Haig DA and Clarke MC. Does the agent of scrapie replicate without nucleic acid? Nature 1967, 214: 764-766.
4. Griffith JS. Self-replication and scrapie. Nature 1967, 215: 1043-1044.
5. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216: 136-144.
6. Bolton DC, McKinley MP and Prusiner SB. Identification of a protein that purifies with the scrapie prion. Science 1982, 218: 1309-1311.
7. McKinley MP, Bolton DC and Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell 1983, 35: 57-62.
8. Gabizon R, McKinley MP, Groth D and Prusiner SB. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci USA 1988, 85: 6617-6621.
9. Biasini E, Turnbaugh JA, Unterberger U and Harris DA. Prion protein at the crossroads of physiology and disease. Trends Neurosci 2012, 25: 92-103.
10. Saborio GP, Permanne B and Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411: 810-813.
11. Castilla J, Saá P, Hetz C and Soto C. In vitro generation of infectious scrapie prions. Cell 2005, 121: 195-206.
12. Makarava N, Savtchenko R and Baskakov IV. Selective amplification of classical and atypical prions using modified protein misfolding cyclic amplification. J Biol Chem 2013, 288: 33-41.
13. Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho MV and Soto C. Protein misfolding cyclic amplification of infectious prions. Nat Protoc 2012, 7: 1397-1409.
14. Basler K, Oesch B, Scott M, Westaway D, Wälchli M, Groth DF and McKinley MP, et al. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 1986, 46: 417-428.
15. Aguzzi A and Falsig J. Prion propagation, toxicity and degradation. Nat Neurosci 2012, 15: 936-939.
16. Winkler J, Tyedmers J, Bukau B and Mogk A. Hsp70 targets Hsp100 chaperones to substrates for protein disaggregation and prion fragmentation. J Cell Biol 2012, 198: 387-404.
17. Aguzzi A and Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009, 89: 1105-1152.
18. Cortez LM, Kumar J, Renault L, Young HS and Sim VL. Mouse prion protein polymorphism Phe-108/Val-189 affects the kinetics of fibril formation and the response to seeding. J Biol Chem 2013, 288: 4772-4781.
19. Nyström S, Mishra R, Hornemann S, Aguzzi A, Nilsson KP and Hammarström P. Multiple substitutions of methionine 129 in human prion protein reveal its importance in the amyloid fibrillation pathway. J Biol Chem 2012, 287: 25975-25984.
20. Younan ND, Nadal RC, Davies P, Brown DR and Viles JH. Methionine oxidation perturbs the structural core of the prion protein and suggests a generic misfolding pathway. J Biol Chem 2012, 28: 28263-28275.
21. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF and Caughey B. The most infectious prion protein particles. Nature 2005, 437: 257-261.
22. Klingeborn M, Race B, Meade-White KD, Rosenke R, Striebel JF and Chesebro B. Crucial role for prion protein membrane anchoring in the neuroinvasion and neural spread of prion infection. J Virol 2011, 85: 1484-1494.
23. Imamura M, Kato N, Yoshioka M, Okada H, Iwamaru Y, Shimizu Y, Mohri S and Yokoyama T, et al. Glycosylphosphatidylinositol (GPI) anchordependent stimulation pathway required for generation of baculovirusderived recombinant scrapie prion protein. J Virol 2011, 85: 2582-2588.
24. Bate C and Williams A. Neurodegeneration induced by the clustering of sialylated glycosylphosphatidylinositols of prion proteins. J Biol Chem 2012, 287: 7935-7944.
25. Raymond GJ, Race B, Hollister JR, Offerdahl DK, Moore RA, Kodali R and Raymond LD, et al. Isolation of novel synthetic prion strains by amplification in transgenic mice coexpressing wild-type and anchorless prion proteins. J Virol 2012, 86: 11763-11778.
26. Cancellotti E, Bradford BM, Tuzi NL, Hickey RD, Brown D, Brown KL and Barron RM, et al. Glycosylation of PrPC determines timing of neuroinvasion and targeting in the brain following transmissible spongiform encephalopathy infection by a peripheral route. J Virol 2010, 84: 3464-3475.
27. Cancellotti E, Mahal SP, Somerville R, Diack A, Brown D, Piccardo P and Weissmann C, et al. Post-translational changes to PrP alter transmissible spongiform encephalopathy strain properties. EMBO J 2013, 32: 756-769.
28. Salamat MK, Dron M, Chapuis J, Langevin C and Laude H. Prion propagation in cells expressing PrP glycosylation mutants. J Virol 2011, 85: 3077-3085.
29. Riesner D. Transmissible spongiform encephalopathies: the prion theory background and basic information. Contrib Microbiol 2004, 11: 1-13.
30. Wang F, Zhang Z, Wang X, Li J, Zha L, Yuan CG and Weissmann C, et al. Genetic informational RNA is not required for recombinant prion infectivity. J Virol 2012, 86: 1874-1876.
31. Kim JI, Cali I, Surewicz K, Kong Q, Raymond GJ, Atarashi R and Race B, et al. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 2010, 285: 14083-14087.
32. Prusiner SB. Unifying role for prions in neurodegenerative diseases. Science 2012, 336: 1511-1513.
33. Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012, 149: 968-977.
34. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T and Tayler K, et al. Prion-like behaviour and Tau-dependent cytotoxicity of pyroglutamylated amyloid-b. Nature 2012, 485: 651-655.
35. Polymenidou M and Cleveland DW. The seeds of neurodegeneration: prionlike spreading in ALS. Cell 2011, 147: 498-508.
36. Stöhr J, Weinmann N, Wille H, Kaimann T, Nagel-Steger L, Birkmann E and Panza G, et al. Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci USA 2008, 105: 2409-2414.
37. Lee YJ, Savtchenko R, Ostapchenko VG, Makarava N and Baskakov IV. Molecular structure of amyloid fibrils controls the relationship between fibrillar size and toxicity. PLoS ONE 2011, 6: e20244.
38. Eisenberg D and Jucker M. The amyloid state of proteins in human diseases. Cell 2012, 148: 1188-1203.
39. Baker HF, Ridley RM, Duchen LW, Crow TJ and Bruton CJ. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol 1994, 8: 25-39.
40. Bibow S, Mukrasch MD, Chinnathambi S, Biernat J, Griesinger C, Mandelkow E and Zweckstetter M. The dynamic structure of filamentous Tau. Angew Chem Int Ed Engl 2011, 50: 11520-11524.
41. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ and Lee VM. Synthetic Tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 2013, 33: 1024-1037.
42. Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J and Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem 2012, 287: 20522-20533.
43. Flach K, Hilbrich I, Schiffmann A, Gärtner U, Krüger M, Leonhardt M and Waschipky H, et al. Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem 2012, 287: 43223-43233.
44. Kfoury N, Holmes BB, Jiang H, Holtzman DM and Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 2012, 287: 19440-19451.
45. Yu X, Luo Y, Dinkel P, Zheng J, Wei G, Margittai M and Nussinov R, et al. Cross-seeding and conformational selection between three- and four-repeat human Tau proteins. J Biol Chem 2012, 287: 14950-14959.
46. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A and Fraser G, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009, 11: 909-913.
47. Guo JL and Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011, 286: 15317-15331.
48. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ and Pitstick R, et al. Propagation of Tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73: 685-697.
49. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E and Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew Chem Int Ed Engl 2013, 52: 1-6.
50. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ and Lee VM. The acetylation of Tau inhibits its function and promotes pathological Tau aggregation. Nat Commun 2011, 2: 252.
51. Zhu HL, Fernández C, Fan JB, Shewmaker F, Chen J, Minton AP and Liang Y. Quantitative characterization of heparin binding to Tau protein: implication for inducer-mediated Tau filament formation. J Biol Chem 2010, 285: 3592-3599.
52. Mo ZY, Zhu YZ, Zhu HL, Fan JB, Chen J and Liang Y. Low micromolar zinc accelerates the fibrillization of human Tau via bridging of Cys-291 and Cys-322. J Biol Chem 2009, 284: 34648-34657.
53. Zhu HL, Meng SR, Fan JB, Chen J and Liang Y. Fibrillization of human Tau is accelerated by exposure to lead via interaction with His-330 and His-362. PLoS ONE 2011, 6: e25020.
54. Meng SR, Zhu YZ, Guo T, Liu XL, Chen J and Liang Y. Fibril-forming motifs are essential and sufficient for the fibrillization of human Tau. PLoS ONE 2012, 7: e38903.
55. Valentine JS, Doucette PA and Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 2005, 74: 563-593.
56. Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R and Julien JP. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006, 9: 108-118.
57. Jacobsson J, Jonsson PA, Andersen PM, Forsgren L and Marklund SL. Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without Cu,Zn-superoxide dismutase mutations. Brain 2001, 124: 1461-1466.
58. Urushitani M, Ezzi SA and Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2007, 104: 2495-2500.
59. Munch C, O'Brien J and Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 2011, 108: 3548-3553.
60. Grad LI, Guest WC, Yanai A, Pokrishevsky E, O'Neill MA, Gibbs E and Semenchenko V, et al. Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc Natl Acad Sci USA 2011, 108: 16398-16403.
61. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P and Goolsby H, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010, 13: 1396-1403.
62. Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA and Trotti D, et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci USA 2012, 109: 5074-5079.
63. Chattopadhyay M, Durazo A, Sohn SH, Strong CD, Gralla EB, Whitelegge JP and Valentine JS. Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc Natl Acad Sci USA 2008, 105: 18663-18668.
64. Ma Q, Fan JB, Zhou Z, Zhou BR, Meng SR, Hu JY and Chen J, et al. The contrasting effect of macromolecular crowding on amyloid fibril formation. PLoS ONE 2012, 7: e36288.
65. Zhou HX, Rivas G and Minton AP. Macromolecular crowding and confinement: biochemical, biophysical, and potential physiological consequences. Annu Rev Biophys 2008, 37: 375-397.
66. Zhou Z, Fan JB, Zhu HL, Shewmaker F, Yan X, Chen X and Chen J, et al. Crowded cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding. J Biol Chem 2009, 284: 30148-30158.
67. Zhou Z, Yan X, Pan K, Chen J, Xie ZS, Xiao GF and Yang FQ, et al. Fibril formation of the rabbit/human/bovine prion proteins. Biophys J 2011, 101: 1183-1492.
68. Finn TE, Nunez AC, Sunde M and Easterbrook-Smith SB. Serum albumin prevents protein aggregation and amyloid formation and retains chaperonelike activity in the presence of physiological ligands. J Biol Chem 2012, 287: 21530-21540.
69. Aguzzi A and Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64: 783-790.